Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N) on January 27, 2022. The consideration will be paid with a combination of cash and warrants to purchase the Company's common stock. On January 24, 2022, as consideration for entering into the LOI, the Company issued warrants to purchase 2,311,404 shares of the Company's Common Stock, subject to certain adjustments. The transaction is subject to finalization of due diligence investigations by the parties, the negotiation and execution of definitive transaction agreements and other customary closing conditions including certain funding requirements.

Ocugen, Inc. (NasdaqCM:OCGN) cancelled the acquisition of a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N) on September 30, 2022. As of September 30, 2022, the Liminal Warrants were cancelled as a result of the termination of the LOI.